Beyond Air (XAIR) to Release Earnings on Friday

Beyond Air (NASDAQ:XAIR) is expected to release its Q3 2026 results before the market opens on Friday, February 13th. Analysts expect Beyond Air to post earnings of ($0.54) per share and revenue of $2.1460 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Friday, February 13, 2026 at 8:00 AM ET.

Beyond Air (NASDAQ:XAIR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.15). The company had revenue of $1.82 million for the quarter, compared to analysts’ expectations of $2.54 million. Beyond Air had a negative return on equity of 261.08% and a negative net margin of 632.51%. On average, analysts expect Beyond Air to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Beyond Air Stock Performance

NASDAQ XAIR opened at $1.04 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 3.73 and a current ratio of 4.24. The stock’s fifty day moving average is $1.15 and its two-hundred day moving average is $1.83. The firm has a market capitalization of $8.33 million, a P/E ratio of -0.14 and a beta of 0.39. Beyond Air has a fifty-two week low of $0.67 and a fifty-two week high of $8.12.

Institutional Investors Weigh In On Beyond Air

A number of institutional investors have recently modified their holdings of XAIR. Geode Capital Management LLC lifted its stake in Beyond Air by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock worth $144,000 after acquiring an additional 12,598 shares in the last quarter. Virtu Financial LLC purchased a new stake in Beyond Air during the third quarter worth about $48,000. Osaic Holdings Inc. lifted its position in shares of Beyond Air by 26.4% during the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after purchasing an additional 34,000 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Beyond Air in the third quarter valued at approximately $1,753,000. 31.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on XAIR. Weiss Ratings reissued a “sell (e)” rating on shares of Beyond Air in a research report on Monday, December 22nd. Rodman & Renshaw initiated coverage on shares of Beyond Air in a research note on Tuesday, January 20th. They issued a “buy” rating for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Beyond Air in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.00.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.